The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer
Goutam Chakraborty(National Centre for Cell Science), Philip W. Kantoff(Convergent Science (United States)), Nagavarakishore Pillarsetty(Memorial Sloan Kettering Cancer Center), Michael J. Morris(Dana-Farber Cancer Institute), Bastien Nguyen(Eli Lilly (United States)), Tiffany A. Traina(Memorial Sloan Kettering Cancer Center), Pedram Razavi(Memorial Sloan Kettering Cancer Center), Stephen B. Solomon(Memorial Sloan Kettering Cancer Center), Nikolaus Schultz(Memorial Sloan Kettering Cancer Center), Jeremy C. Durack(Memorial Sloan Kettering Cancer Center), Gwo‐Shu Mary Lee(Dana-Farber Cancer Institute), Andreas G. Wibmer(Memorial Sloan Kettering Cancer Center), Romina Ghale(Memorial Sloan Kettering Cancer Center), Ying Z. Mazzu(Memorial Sloan Kettering Cancer Center), Lorelei A. Mucci(American Cancer Society), Konrad H. Stopsack(Memorial Sloan Kettering Cancer Center), Wassim Abida(Memorial Sloan Kettering Cancer Center), Howard I. Scher(Memorial Sloan Kettering Cancer Center), Christoph Kreitzer(Memorial Sloan Kettering Cancer Center), Subhiksha Nandakumar(Memorial Sloan Kettering Cancer Center), Rahim Hirani(New York Medical College), Sai Harisha Rajanala(Memorial Sloan Kettering Cancer Center), Matthew G. Vander Heiden(Broad Institute)
Cited by 51
Related Papers
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.5k
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k